← board
CVKD
distress 9/10 · high distress / dilution risk$2.05-2%today-86% from 52w high
Lead: heparin-induced thrombocytopenia (HIT)
Revenue
pre-revenue
Liquidity
$2M
Runway
0.2 yrs
Shares 1y
+40%
Price & events
-73.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.4%
1D
-12.0%
1W
-33.0%
1M
-62.9%
3M
-71.8%
6M
-82.5%
1Y
-69.8%
2Y
—
5Y
-96.7%
All
Overview
- Market Cap
- $5.88M
- Volume
- 4.75K
- 52 Week Range
- $2.05 – $14.20
- Total Shares
- 2.87M
- Float Shares
- 2.44M
- Short %
- 3.13%
- % Held by Insiders
- 14.84%
- % Held by Institutions
- 3.30%
- RVOL
- 0.05x
- Beta
- 1.75
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 5
- projected NDA submission in 2029Guided 40%regulatory submissionFiled (NDA/BLA)CAD-1005 · NDA submission for CAD-1005 in HITSEC 8-K
- June 22–25, 2026conferencedata presentationsecondaryCAD-1005, tecarfarin · Present dual-track strategy at BIO International Convention.SEC 8-K
- 2026-04-30fda agreementCAD-1005 · Completed End-of-Phase 2 meeting with FDA and received guidance on Phase 3 trial designSEC 8-K
- 2025-12-10partnershipVLX-1005 · Cadrenal acquires all assets related to VLX-1005 and backup compounds from Veralox, including IP and license agreementSEC 8-K
- 2025-09-12partnershipAcquired eXIthera's portfolio of Factor XIa inhibitors including frunexian and EP-7327.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $28 (+1250% upside) · 3 analysts
- 2026-04-07HC Wainwright & Co.Buy
- 2025-05-16HC Wainwright & Co.Buy
- 2024-11-11HC Wainwright & Co.Buy
Competitors — heparin-induced thrombocytopenia (HIT)
- none identified
Recent news
- 2026-07-21Cadrenal Therapeutics, Inc. SEC Filing (Jul 21, 2026) - Stock Titan
- 2026-07-21Cadrenal seeks partners for cardiac care drug portfolio - Investing.com
- 2026-07-21Cadrenal's Phase 2 data show >25% absolute reduction in clotting events - Stock Titan
- 2026-07-21Cadrenal Therapeutics Launches Partnering Process as Its - GlobeNewswire
- 2026-07-17Cadrenal Therapeutics (NASDAQ: CVKD) outlines CMO Ferguson's exit deal - Stock Titan
- 2026-07-15Cadrenal Therapeutics (CVKD) outlines $8.84M Rule 506(b) warrant financing - Stock Titan
- 2026-07-13Cadrenal Therapeutics Presents Positive Phase 2 CAD-1005 Data in Late-Breaking ISTH Oral Presentation for Heparin-Induced Thrombocytopenia - Quiver Quantitative
- 2026-07-13Cadrenal presents phase 2 data for CAD-1005 at ISTH congress - Investing.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.